MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
17.96
-0.29
-1.59%
After Hours: 18.15 +0.19 +1.06% 19:30 08/21 EDT
OPEN
18.44
PREV CLOSE
18.25
HIGH
18.54
LOW
17.83
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
20.22
52 WEEK LOW
6.93
MARKET CAP
2.56B
P/E (TTM)
-52.4227
1D
5D
1M
3M
1Y
5Y
1D
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Seeking Alpha · 1d ago
Weekly Report: what happened at TRVI last week (0810-0814)?
Weekly Report · 4d ago
Trevi Therapeutics Price Target Raised to $28.00/Share From $24.00 by Jones Trading
Dow Jones · 08/14 13:01
Trevi Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 08/14 13:01
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Benzinga · 08/14 12:52
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
TipRanks · 08/13 19:35
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
TipRanks · 08/11 10:15
Weekly Report: what happened at TRVI last week (0803-0807)?
Weekly Report · 08/10 09:06
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.